Drug intelligence / Profile preview

AIP 302

Development stage: Preclinical
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AIP 302 is an investigational diagnostic radiopharmaceutical being developed by Advanced Innovative Partners (AIP) for the imaging and detection of lung cancer. As a diagnostic agent within AIP's oncology-focused pipeline, it is designed to utilize a targeting moiety to deliver a radioisotope to lung cancer cells, allowing for visualization through nuclear medicine imaging techniques such as PET or SPECT. The program is currently in the IND-enabling phase, with the developer conducting preclinical studies and preparing regulatory filings to support an Investigational New Drug (IND) application for clinical entry.

Other names: AIP 302-AIP-radiopharmaceutical-Lung Cancer (Diagnostic)

Beyond the preview

Go deeper on AIP 302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP 302.

Explore the full profile